Incyte shares rise on strong Q4 revenue, Opzelura growth
Biotech revenue up 28% year-over-year to $1.51 billion, company raises 2026 outlook
Incyte shares moved higher in after-hours trading Tuesday after the biotechnology company reported fourth-quarter revenue of $1.51 billion, exceeding analyst expectations and signaling robust demand for its core blood cancer and immunology treatments.
The Wilmington, Delaware-based company delivered net product revenue of $1.22 billion for the quarter, representing a 20% increase year-over-year. The performance was driven primarily by its flagship drug Jakafi, which generated $828.2 million in sales, up 7% from the prior year, and Opzelura, a topical treatment for atopic dermatitis and vitiligo, which surged 28% to $207.3 million.
"We delivered another year of strong financial performance in 2025, highlighted by double-digit revenue growth across our key products," said Hervé Hoppenot, chief executive officer of Incyte. "Our disciplined execution and focus on innovation position us well for continued growth in 2026 and beyond."
For the full year 2025, Incyte reported total revenue of $5.14 billion, a 21% increase compared with the previous year. Net product revenue reached $4.35 billion, exceeding the company's previously issued guidance. The company ended the year with a strong balance sheet, holding cash, cash equivalents, and marketable securities of $3.6 billion as of December 31, 2025.
Incyte provided 2026 guidance for total net product revenue between $4.77 billion and $4.94 billion, representing continued growth despite anticipated headwinds. The company projects Jakafi sales will reach $3.22 billion to $3.27 billion, while Opzelura is expected to generate $750 million to $790 million.
The revenue growth comes at a critical juncture for Incyte, which faces increasing competition in the myelofibrosis market. Jakafi, approved for myelofibrosis and polycythemia vera, has faced pressure from newer treatments including Sierra Oncology's momelotinib and GSK's Ojjaara. However, the drug's continued growth demonstrates its resilience and strong market positioning.
Opzelura's 28% surge in the fourth quarter underscores the treatment's expanding reach in dermatology. The cream, approved for atopic dermatitis and vitiligo, represents Incyte's diversification beyond oncology into immunology, a strategy that has begun to yield dividends as sales acceleration accelerates.
Analysts have maintained a cautiously optimistic outlook on Incyte shares. The stock currently trades at approximately 18 times trailing earnings, with a consensus price target of $104.23, suggesting modest upside from current levels. The company's forward price-to-earnings ratio of 14.41 indicates that investors are pricing in expectations for continued growth.
Incyte's strong cash position provides strategic flexibility as the company continues to invest in its pipeline and explores potential business development opportunities. The company has advanced several oncology candidates through clinical development, including treatments for solid tumors and hematologic malignancies.
Looking ahead, investors will focus on Opzelura's ability to maintain its growth trajectory and Jakafi's resilience against competitive pressures. The company's ability to execute on its clinical development programs and potentially expand Opzelura into additional indications could drive further revenue growth in the coming years.
The biotechnology sector has experienced renewed investor interest in 2026, driven by improving clinical readouts and merger and acquisition activity. Incyte's combination of established commercial products and developing pipeline positions it as a potential beneficiary of this trend, particularly given its strong financial foundation and proven commercial execution capabilities.